Drugs / PDC-APB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04853823 | Nov 2021 → Nov 2022 | contact dermatitis | Hapten Sciences, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT02700373 | Mar 2016 → Jan 2018 | contact dermatitis | Hapten Sciences, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PDC-APB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02700373 ↗ |
| Route | Intramuscular | “PDC-APB by intramuscular (IM) injection compared to placebo” NCT02700373 ↗ |